文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

心房颤动合并急性冠脉综合征:强效抗血小板药双联抗栓的随机对照试验

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.
PubMed 文献 · Nat Med · 2026-08-29

EPIDAURUS 试验为开放标签随机对照试验,旨在评估心房颤动合并急性冠脉综合征患者使用 DOAC 联合强效 P2Y12 抑制剂(普拉格雷或替格瑞洛)1 个月方案,对比 DOAC 联合氯吡格雷及院内阿司匹林的疗效与安全性。因数据与安全监察委员会提出安全担忧,试验在入组 602 例(预期 1,474 例)后提前终止;探索性分析显示强效 P2Y12 抑制剂组出血率更高,且未明显降低缺血并发症风险。

要点

  • 在心房颤动合并急性冠脉综合征患者中,DOAC 联合强效 P2Y12 抑制剂较氯吡格雷方案出血率更高。
  • 强效 P2Y12 抑制剂联合 DOAC 未显示明显降低缺血事件风险。
  • 该研究结果不支持在此类患者中常规使用强效 P2Y12 抑制剂联合 DOAC。

核心结论

  • 在心房颤动合并急性冠脉综合征患者中,DOAC 联合强效 P2Y12 抑制剂(普拉格雷或替格瑞洛)1 个月方案较 DOAC 联合氯吡格雷及院内阿司匹林出血率更高,且未明显降低缺血并发症风险,不支持常规使用。

研究设计与样本

  • EPIDAURUS 为开放标签随机对照试验,计划入组 1,474 例心房颤动合并急性冠脉综合征患者,实际入组 602 例(154 例女性)后因安全担忧提前终止。

主要发现

  • 探索性分析显示,与氯吡格雷及院内阿司匹林相比,强效 P2Y12 抑制剂与更高出血率相关,且未明显降低缺血并发症风险。
  • 主要结局为随机化后 6 周评估的疗效终点(复发性缺血事件)及安全性终点(包括死亡和大出血),采用单独的 win-loss ratio 分析。

临床怎么用

  • 在心房颤动合并急性冠脉综合征患者中,不应常规采用 DOAC 联合强效 P2Y12 抑制剂(普拉格雷或替格瑞洛)方案。

局限性

  • 试验因安全担忧提前终止,实际入组 602 例,低于预期的 1,474 例。
  • 研究为开放标签设计。
  • 出血类型 ≥2 和 ≥3(BARC 量表)的分析为探索性次要安全性终点分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The selection of the optimal antithrombotic regimen in patients with atrial fibrillation and acute coronary syndrome remains challenging. Previous trials have demonstrated that dual antithrombotic therapy (DAT), consisting of direct oral anticoagulants (DOACs) plus a P2Y12 inhibitor, reduces bleeding compared to a triple-therapy regimen using vitamin K antagonists. However, subsequent meta-analyses have suggested an increased risk of ischemic events with DAT, particularly within the first month of treatment. Clopidogrel has been the predominant P2Y12 inhibitor used across these studies, despite the risk of high on-treatment platelet reactivity when using this drug. In this study, we conducted an open-label, randomized controlled trial (EPIDAURUS) in patients with atrial fibrillation and acute coronary syndrome, designed to assess the efficacy and safety of a 1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) compared to DOAC plus clopidogrel and in-hospital aspirin. The primary outcomes of the trial were an efficacy endpoint, recurrent ischemic events and safety endpoints, including death and major bleeding, which were evaluated 6 weeks after randomization using separate win-loss ratio analyses. The study was prematurely terminated after enrollment of 602 patients (154 female) of an expected 1,474 patients, owing to safety concerns raised by the Data and Safety Monitoring Board. Exploratory analyses of secondary safety endpoints, including bleeding type ≥2 and ≥3 according to the Bleeding Academic Research Consortium scale, revealed that, compared to clopidogrel and in-hospital aspirin, treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications. These findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population. ClinicalTrials.gov identifier: NCT04981041 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Rizas KD, Mourouzis K, Rath D, et al. Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial. Nat Med. 2026. PMID: 42668287. doi:10.1038/s41591-026-04629-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。